The transcription factor interferon regulatory factor 5 (IRF5) has previously been implicated in systemic lupus erythematosus (SLE) development, but its precise role in this process is unknown.

Through clinical trials researchers can test new therapeutic approaches that over time may bring new treatments to people with lupus. Keep up to date with the latest CAR cell research, including ...

Long-lived plasma cells, which produce autoantibodies in diseases such as systemic lupus erythematosus (SLE), are an as yet unexplored therapeutic target in such antibody-mediated disorders.

In this groundbreaking treatment for lupus, the immune system's primary defence cells known as T-cells were ... We are proud to see the patient return to normal life, free from immunosuppressant ...

Objective Combination therapy with rituximab and belimumab is a novel treatment strategy for severe SLE and lupus nephritis.

The FDA has granted Fast Track designation to ADI-001 for the treatment of refractory systemic lupus erythematosus with extrarenal involvement.